临床实践中增殖性糖尿病视网膜病变抗VEGF单药治疗的视觉结局与依从性挑战
基于Vestrum Health视网膜数据库的回顾性队列研究纳入2016至2021年间26632只未治疗过的增殖性糖尿病视网膜病变眼,评估抗VEGF治疗与Protocol S的一致性及6个月护理间隔。合并糖尿病黄斑水肿且与Protocol S一致的眼两年平均视力提高3.0个字母,不一致眼下降0.6个字母;超过40%患者一年内失访,第一年内出现6个月护理间隔者两年时玻璃体切除术、视网膜脱离和新生血管性青光眼发生率更高。
要点
- 合并糖尿病黄斑水肿且与Protocol S一致的眼两年视力提高3.0个字母,不一致眼下降0.6个字母。
- 超过40%的患者在一年内失访,第一年内出现6个月护理间隔者两年时玻璃体切除术、视网膜脱离和新生血管性青光眼发生率更高。
- 合并糖尿病黄斑水肿者更可能与Protocol S一致,ETDRS字母评分大于70者较24至40者更不可能与Protocol S一致。
核心结论
- 增殖性糖尿病视网膜病变抗VEGF单药治疗所需的频繁随访和重复治疗可能对维持所需计划构成挑战,并可能导致更差的视力结局和更多的眼部并发症。
研究设计与样本
- 回顾性队列研究,使用Vestrum Health视网膜数据库,纳入2016至2021年间26632只因增殖性糖尿病视网膜病变接受抗VEGF注射的未治疗眼。
主要发现
- 合并糖尿病黄斑水肿且与Protocol S一致的眼两年平均视力提高3.0个字母,不一致眼下降0.6个字母。
- 超过40%的患者在一年内失访。
- 第一年内出现6个月护理间隔者两年时玻璃体切除术、视网膜脱离和新生血管性青光眼发生率更高。
- 合并糖尿病黄斑水肿者更可能与Protocol S一致,ETDRS字母评分大于70者较24至40者更不可能与Protocol S一致。
关键数值与推荐
- 与Protocol S一致定义为基线后14周内接受四次抗VEGF注射。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate practice patterns and long-term complications of proliferative diabetic retinopathy (PDR) treatment outside DRCR's Protocol S. METHODS: A retrospective cohort study using Vestrum Health Retina Database included 26,632 treatment-naive eyes receiving anti-VEGF injections for PDR between 2016-2021. Primary outcomes were concordance with Protocol S, defined as four anti-VEGF injections within 14 weeks of baseline, and 6-month gaps in care, assessed via multivariable logistic regressions. RESULTS: Among eyes with DME, those concordant with Protocol S had mean VA gain of +3.0 letters compared to -0.6 letters among those not concordant with Protocol S at two years. Over 40% of patients became loss to follow up within one year. Those experiencing 6-month gaps in care within the first year had higher rates of vitrectomy, retinal detachment, and neovascular glaucoma at two years. Patients with DME were more likely to be concordant while those with ETDRS letter score >70 were less likely to be concordant with Protocol S regimen relative to those without DME and ETDRS letter score between 24-40, respectively. CONCLUSION: The frequent follow-up appointments and repeat treatments necessary for anti-VEGF monotherapy in PDR can pose challenges to maintaining the required schedule and can result in worse visual acuity outcomes and increased ocular complications.
引用
- Maturi JR, Boucher N, Fernando R, et al. Visual outcomes and adherence challenges in proliferative diabetic retinopathy anti-VEGF monotherapy in the clinical practice setting. Retina. 2025. PMID: 40068211. doi:10.1097/IAE.0000000000004440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。